- |||||||||| doxorubicin hydrochloride / Generic mfg.
Review, Journal, BRCA Biomarker: Complex Interplay between DNA Damage and Autophagy in Disease and Therapy. (Pubmed Central) - Aug 31, 2024
Chemotherapeutic agents like doxorubicin (Dox) have shown efficacy against various cancers but are hindered by dose-dependent cytotoxicity, particularly on vital organs like the heart and brain...Additionally, emerging evidence suggests a potential link between autophagy, DNA damage, and caretaker breast cancer genes BRCA1/2, highlighting the interplay between DNA repair mechanisms and cellular homeostasis. This review explores the intricate relationship between cancer, Dox-induced cytotoxicity, autophagy modulation, and the potential implications of autophagy in DNA damage repair pathways, particularly in the context of BRCA1/2 mutations.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Insights into yeast response to chemotherapeutic agent through time series genome-scale metabolic models. (Pubmed Central) - Aug 31, 2024
This review explores the intricate relationship between cancer, Dox-induced cytotoxicity, autophagy modulation, and the potential implications of autophagy in DNA damage repair pathways, particularly in the context of BRCA1/2 mutations. The flux samples were clustered using machine learning techniques, and the clusters' functional analysis was performed using reaction set enrichment analysis.
- |||||||||| metformin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Melatonin and Metformin Mitigate Doxorubicin-Induced Alveolar Bone Toxicity. (Pubmed Central) - Aug 31, 2024
Although cotreatment with melatonin or metformin resulted in some improvement in these parameters, cotreatment with melatonin was more effective than cotreatment with metformin in terms of decreasing oxidative stress, reducing bone resorption, and improving microarchitecture and periodontal condition. All of these findings highlight the potential for antioxidants, especially melatonin, to ameliorate doxorubicin-induced alveolar bone toxicity.
- |||||||||| Scemblix (asciminib) / Novartis, Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia can be Treated with Chemotherapy-Free Regimens without Transplant () - Aug 30, 2024 - Abstract #SOHO2024SOHO_1039;
All of these findings highlight the potential for antioxidants, especially melatonin, to ameliorate doxorubicin-induced alveolar bone toxicity. Significant progress has been made in recent years in the treatment of adults with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL).1 Combining BCR::ABL1 tyrosine kinase inhibitors (TKIs) with intensive chemotherapy regimens like hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) and others has greatly improved patient outcomes.2 As a result, allogeneic hematopoietic stem cell transplantation (HSCT) has become an additional valuable option...Specifically, the 5-year PFS rates were 81% with hyper-CVAD plus ponatinib, 54% with hyper-CVAD plus dasatinib, and 64% with hyper-CVAD plus imatinib...In contrast to the D-ALBA trial, only two patients underwent HSCT.26 Whether the combination of blinatumomab and ponatinib can overcome the poor prognosis of IKZF1plus and the negative impact of an elevated white blood cell count (higher than 70
- |||||||||| The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma () - Aug 30, 2024 - Abstract #SOHO2024SOHO_1030;
P1, P1/2,
Additionally, studies assessing the efficacy and safety of iberdomide (NCT06179888) and mezigdomide (NCT06048250) as maintenance agents post idecabtagene vicleucel are underway...Furthermore, a distinct benefit to patients currently receiving CAR-T is the possibility of experiencing a prolonged treatment-free interval afterwards,25 and the routine prescription of maintenance will change this radically. Moreover, maintenance therapy after CAR-T may also lead to increased patient financial toxicity and increase financial burdens on health care systems,26 noting the already high cost of CAR-T therapies.
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Management of High-Grade B-Cell Lymphoma () - Aug 30, 2024 - Abstract #SOHO2024SOHO_1026;
An important consideration is the potential use of Pola-RCHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) among patients with HGBL...Ongoing trials evaluating firstline CAR T-cell therapy for aggressive B-cell lymphomas, or combinations of bispecific antibodies with chemotherapy, might provide insight into the responsiveness of HGBL to adoptive immunotherapy. Additional research should focus on biologically rational treatments for HGBL that account for their highly proliferative nature, frequent MYC rearrangements, TP53 mutations, and immune-deserted microenvironment.
- |||||||||| doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
The Outcome of Management of Multiple Myeloma in Sudanese Patients (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_933;
The VAD regimen was the primary treatment used. There was a significant improvement in laboratory parameters (total protein, albumin, calcium, and ESR levels).
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Uncharted Territory: Innovative Regimen Treating Composite Lymphoma in Hodgkin's Survivors (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_837;
There was a significant improvement in laboratory parameters (total protein, albumin, calcium, and ESR levels). Case Description: We report a case of a 62-year-old male patient diagnosed in July 2022 with classical Hodgkin lymphoma, stage IIIB, International Prognostic Score (IPS) 3 for which he received 2 cycles of Adriamycin
- |||||||||| Rituxan (rituximab) / Roche
Cutaneous Large B-Cell Lymphoma on Scalp: Case Presentation (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_805;
The diagnosis was confirmed through comprehensive histopathological and immunohistochemical analysis. Early recognition and treatment with R-CHOP chemotherapy led to satisfactory clinical outcomes.
- |||||||||| Rituxan (rituximab) / Roche
Primary Mediastinal B-Cell Lymphoma: Experience at a General Hospital in Houston, Texas (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_774;
Although dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) represents one of the treatment options for this entity, the optimal first-line therapy for PMBCL remains controversial. The DA-EPOCH-R regimen without consolidation radiotherapy can be considered an effective therapy with a high cure rate in managing PMBCL and avoiding long-term toxicity from radiation.
- |||||||||| Rituxan (rituximab) / Roche
Diffuse Large B-Cell Lymphoma of the Bone Recurring in the Skin: A Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_770;
No cases of recurrence in the skin after the bone being the primary site have been reported. This case highlights the unique presentation and recurrence pattern of PLB, emphasizing the importance of vigilant follow-up and innovative treatments such as CAR T-cell therapy.
- |||||||||| Rituxan (rituximab) / Roche
Diagnosis and Treatment of Primary Hepatic Lymphoma: Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_739;
It is difficult to make specific treatment recommendations for primary liver lymphoma. The course of treatment is based on the underlying pathological processes, the stage of the disease, and other confirmed prognostic factors.
- |||||||||| A Rare Case of Plasmablastic Lymphoma Presenting With a Bulky Renal Mass in an Immunocompetent Patient (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_732;
Intensive chemotherapy combined with antimyeloma drugs such as proteasome inhibitors, immunomodulators, and monoclonal antibodies provides significant improvement in PBL, but the management of PBL remains challenging. The aggressive nature and propensity for relapse indicate an ongoing need for clinical studies with large case series, especially patients with relapsed and resistant PBL.
- |||||||||| Rituxan (rituximab) / Roche
Experience in Diagnosis and Management of Lymphoma in Conception (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_695;
Patients with HL received ABVD with omission of bleomycin; those who relapsed received BEACOPP with reduced dose (25%) of bleomycin...Before chemotherapy, 3 patients received (R-CHOP) after their 20th week of gestation fractionated over 2 days, with reduced adriamycin dose (25%)... The major challenge was to stage and optimize the treatment approach offered to the mother, while limiting the impact on the fetus.
- |||||||||| Opdivo (nivolumab) / BMS, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Rare Cases of Hodgkin Lymphoma Transformation in Chronic Lymphocytic Leukemia: Challenges in Diagnosis and Management (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_692;
Understanding the underlying mechanisms, such as shared genetic aberrations and immune dysregulation, is crucial for developing targeted therapies. Management requires a multidisciplinary approach, considering disease burden, prognostic markers, and patient factors.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
From Hodgkin Lymphoma to Mycosis Fungiodes: A Quick Cascade (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_690;
He underwent treatment with adriamycin, bleomycin sulfate, vinblastine sulfate, and dacarbazine...Brentuximab had previously been discussed; however, advanced disease and the development of multiorgan failure precluded further treatment... Maintaining a broad differential for cutaneous involvement of hematological malignancies is essential; tissue biopsy is vital for prompt and targeted treatment.
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche
Erdheim-Chester Disease: Don't Forget It in Case of Unexplained Retroperitoneal Fibrosis (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_625;
Its first presentation can be an incidental finding of retroperitoneal fibrosis on routine imaging follow-up. Most cases of ECD require treatment, and the choice of therapy must be individualized based on clinical characteristics, disease mutational status, and tolerance of treatment.
- |||||||||| BTK Inhibitors: A Double-Edged (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_519;
Despite the rarity of PBL in patients with CLL, this case underscores the importance of considering the potential for transformation, especially with the widespread use of BTKis. Further research is essential to elucidate the molecular mechanisms driving this transformation, facilitating the development of optimized treatment strategies and improving outcomes for patients with CLL at risk of PBL development.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Evaluation of Liver Function Tests to Identify Hepatotoxicity in Acute Leukemia (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_412;
P
A considerable proportion of patients had hepatotoxicity at diagnosis (20%) with significant reduction in LFTs post induction except for GGT (adriamycin-based regimens). We are including more patients in different stages of chemotherapy protocols to understand the dimensions of hepatic toxicity in AL.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
Venetoclax Added to Hyper-CVADNelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/ Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_368;
P2
The ongoing phase 2 clinical trial of hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone alternating with methotrexate and cytarabine) with nelarabine and pegylated asparaginase (PegAsP) (NCT00501826) has shown promising response rates and survival in adult patients with T-ALL/LBL in the frontline settings (original cohort). Addition of venetoclax to hyper-CVAD-nelarabine-PegAsp is promising and tolerable in the frontline setting for adult patients with T-ALL/LBL.
- |||||||||| ALL in Pregnancy With Challenging Conditions & Side Effects (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_363;
Maintenance Phase: 6-Mercaptopurine (6-MP) The Maintenance Phase interrupted many times because of pancytopenia and hepatotoxicity as an adverse reaction related to (6-MP), so dose was reduced first from 75% then to 50%...Her son, now 8 years old, is doing well, her cardiac function EF 55%. This case is considered uncommon and rare due to the multiple adverse drug reactions; The patient's journey highlights the complexity and challenges of managing All in a pregnant patient.
- |||||||||| Rituxan (rituximab) / Roche
A High-Grade Dural Arteriovenous Fistula With Acute Lymphoblastic Leukemia After Bone Marrow Transplant for Multiple Myeloma: A Therapeutic Dilemma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_331;
Chemotherapy with R-hyper-CVAD (rituximab, cyclophosphamide, vincristine, adriamycin, dexamethasone) with prophylactic intrathecal chemotherapy (methotrexate, cytarabine) was initiated. We describe the diagnosis, treatment, and management of a patient with both Cognard IV d-AVF and ALL, highlighting the complexities of managing 2 serious medical conditions simultaneously, necessitating multidisciplinary care coordination.
- |||||||||| ifosfamide / Generic mfg., mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Solitary Pancreatic Metastasis of Extremity Myxoid Liposarcoma: A Rare Case (Exhibit Hall, Cristal Ballroom) - Aug 28, 2024 - Abstract #CAP2024CAP_294;
Solitary metastasis of extremity myxoid liposarcoma to the pancreas is exceptionally unusual. The present case adds significantly to the current understanding of the metastatic behavior of this entity.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Primary Pulmonary Myxoid Pleomorphic Liposarcoma: An Exceedingly Rare Tumor at an Exceedingly Rare Location (Exhibit Hall, Cristal Ballroom) - Aug 28, 2024 - Abstract #CAP2024CAP_290;
The patient received induction chemotherapy with doxorubicin and subsequently underwent resection...Apart from essential diagnostic criteria based on morphology, desirable diagnostic criteria include absence of FUS/EWSR1-DDIT3 gene fusions and MDM2 amplifications in selected cases. Expert opinion is also advisable.
- |||||||||| Sinonasal Ewing Sarcoma With Both EWSR1-ERG and PMM1-EWSR1 Gene Fusions (Exhibit Hall, Cristal Ballroom) - Aug 28, 2024 - Abstract #CAP2024CAP_279;
He was started on chemotherapy (vincristine, Adriamycin, cyclophosphamide, ifosfamide, etoposide, and mesna) and continues to be followed. This is the first case, to our knowledge, in which Ewing sarcoma occurred in the sinonasal cavity of a nonpediatric patient with both EWSR1-ERG and PMM1-EWSR1 fusions.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Recent advances in CD5+ diffuse large B-cell lymphoma. (Pubmed Central) - Aug 28, 2024
Despite supporting evidence from retrospective studies, it is currently unclear whether dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) can improve outcomes in this population. Several new drugs, such as Bruton tyrosine kinase inhibitors (BTKi), BCL-2 inhibitors, and CXCR4 antagonists, as well as immunotherapy, may help to improve the prognosis of CD5+ DLBCL patients, but additional clinical explorations are needed to determine the optimal therapeutic strategy for this disease.
- |||||||||| Journal: Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development (Pubmed Central) - Aug 27, 2024
In DLBCL patients with an international prognostic index score(IPI score)of 2 or higher, the combination of PV plus rituximab, cyclophosphamide, doxorubicin, and prednisone(PV+R-CHP)extended PFS at 2 years compared with R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), which has long been the standard of care. As shown, ADCs exhibit high therapeutic efficacy in leukemia and lymphoma treatment, but many aspects of their resistance mechanisms remain unclear and require further research.
|
